Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun 130062, China.
Tumor Hospital of Jilin Province, Changchun 130021, China.
Vaccine. 2019 Jul 9;37(30):3981-3988. doi: 10.1016/j.vaccine.2019.05.084. Epub 2019 Jun 5.
Brucellosis is a worldwide zoonosis affecting animal and human health. Till now, there is no effective vaccine licensed for brucellosis in humans. Although M5, H38 and 45/20 vaccines were used to prevent animal brucellosis in the early stages, the currently used animal vaccines are S19, Rev.1, S2, RB51 and SR82. However, these vaccines still have several drawbacks such as residual virulence and interfering conventional serological tests. With the development of DNA recombination technologies and the completion of the sequence of Brucella genome, much research focuses on the search for potential safer and more effective vaccines. Preliminary studies have demonstrated that new vaccines, including genetically engineered attenuated vaccines, subunit vaccines and other potential vaccines, have higher levels of protection, but there are still some problems. In this paper, we briefly review the main vaccines that have been used in controlling the brucellosis for decades and the progress in the development of new brucellosis vaccines.
布鲁氏菌病是一种影响动物和人类健康的世界性动物传染病。到目前为止,人类还没有获得许可用于布鲁氏菌病的有效疫苗。尽管 M5、H38 和 45/20 疫苗曾在早期用于预防动物布鲁氏菌病,但目前使用的动物疫苗是 S19、Rev.1、S2、RB51 和 SR82。然而,这些疫苗仍然存在一些缺点,如残留毒力和干扰常规血清学检测。随着 DNA 重组技术的发展和布鲁氏菌基因组序列的完成,许多研究集中在寻找潜在更安全、更有效的疫苗上。初步研究表明,新型疫苗,包括基因工程减毒疫苗、亚单位疫苗和其他潜在疫苗,具有更高水平的保护,但仍存在一些问题。本文简要综述了几十年来用于控制布鲁氏菌病的主要疫苗以及新型布鲁氏菌病疫苗的发展进展。